Windlas Biotech conducted the conference call for Q4 FY22
Here are the concall highlights
๐งต๐
Here are the concall highlights
๐งต๐
Business Updates:
โข CDMO service revenue stood at 379cr (4% YoY). Chronic & Sub chronic segment has higher revenue share.
โข Received GNP certificate from South Africa which was filed in 2021.
โข EU-GMP inspection completed for plant 4at Dehradun with 0 critical observations.
โข CDMO service revenue stood at 379cr (4% YoY). Chronic & Sub chronic segment has higher revenue share.
โข Received GNP certificate from South Africa which was filed in 2021.
โข EU-GMP inspection completed for plant 4at Dehradun with 0 critical observations.
Industry:
โข In H1, company did face supply chain issue, while the supply chain issue has now been normalized in H2.
Revenue Target for FY22:
- Domestic: 65-70%
- CDS: 15-20%
- Export: 10%
- Injectables: 5-10%
โข In H1, company did face supply chain issue, while the supply chain issue has now been normalized in H2.
Revenue Target for FY22:
- Domestic: 65-70%
- CDS: 15-20%
- Export: 10%
- Injectables: 5-10%
Segmental Revenue:
โข Export business was 20.9cr (up 10.2% YoY) contributing 4% of revenue. (9.5cr for Q4)
โข Company will expand in new geographies and new product will drive export market.
โข Export business was 20.9cr (up 10.2% YoY) contributing 4% of revenue. (9.5cr for Q4)
โข Company will expand in new geographies and new product will drive export market.
CDMO:
โข Revenue for Q4 was 96.9cr (up 11.4% YoY). Contributed 79% of revenue.
- New patent expiry launches
- Increasing wallet share from existing customer
- Foray into injectables
- New customer additon
will drive growth.
โข Chronic segment is expected to show higher growth.
โข Revenue for Q4 was 96.9cr (up 11.4% YoY). Contributed 79% of revenue.
- New patent expiry launches
- Increasing wallet share from existing customer
- Foray into injectables
- New customer additon
will drive growth.
โข Chronic segment is expected to show higher growth.
Customer:
โข Co. is looking to reduce the dependency on single customer.
โข CDMO growth was resulted from new customer.
โข With increase in wider range of services, slowly revenue per customer will increase. For short-term company is looking to add on more customer.
โข Co. is looking to reduce the dependency on single customer.
โข CDMO growth was resulted from new customer.
โข With increase in wider range of services, slowly revenue per customer will increase. For short-term company is looking to add on more customer.
Trade Generics:
โข Revenue for Q4: 14.7cr (up 30.8% YoY). Contributed 13% of consol revenue.
โข Chanel, product & geographic expansion will drive growth for growth. While government policy will help as well.
โข Revenue for Q4: 14.7cr (up 30.8% YoY). Contributed 13% of consol revenue.
โข Chanel, product & geographic expansion will drive growth for growth. While government policy will help as well.
Injectables:
โข Injectable business will be a higher margin business.
โข Sales is expected to begn by end of year, & there may be losses for 1 year or so.
โข Mgmt expect by FY25-26, injectables to deliver its growth
โข Asset Turn: 1.25
Conti.
โข Injectable business will be a higher margin business.
โข Sales is expected to begn by end of year, & there may be losses for 1 year or so.
โข Mgmt expect by FY25-26, injectables to deliver its growth
โข Asset Turn: 1.25
Conti.
โข With investment of 70cr, revenue potential is 175cr with 18-19% of EBIDTA, for injectables business.
Inorganic Business:
โข For inorganic expansion company has criteria of
- Company should be well growing business
- Value addition of company with respect to Windlas.
Inorganic Business:
โข For inorganic expansion company has criteria of
- Company should be well growing business
- Value addition of company with respect to Windlas.
R&D:
โข R&D cost have grown at 16% since 2019, & is expected to reap its benefits in coming years.
โข R&D expense increased by 2.9cr & product registration cost has increased by 1cr, which had drag margin down for CDMO.
โข R&D cost have grown at 16% since 2019, & is expected to reap its benefits in coming years.
โข R&D expense increased by 2.9cr & product registration cost has increased by 1cr, which had drag margin down for CDMO.
Loading suggestions...